Evaluation of effect of Livergol and vitamin E on liver enzyme of nonalcoholic steatohepatitis patients

Phase 2

• Conditions: fatty liver disease.; nonalcoholic steatohepatitis

• Registration Number: IRCT2016111322869N2
• Lead Sponsor: Vice Chancellor for research of Yasuj University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 114

Inclusion Criteria

Major inclusion criteria: Diagnosis of non-alcoholic steatohepatitis disease by sonography and elevated liver enzymes; negative history of autoimmune hepatitis, viral hepatitis, Wilson disease, hemochromatosis, a-1 antitrypsin deficiency, diabetes, hypothyroidism, cardio-pulmonary disease, kidney disease, psychiatric disease, pregnancy, alcohol consumption; also negative history for using lipid lowering drugs such as atorvastatin and gemfibrozil, estrogen, tamoxifen, corticosteroids, amiodarone, acetaminophen more than 2 grams per day, chemotherapy drugs in six months ago, anti-seizure medications such as sodium valproate, carbamazepine, phenytoin, anti-tuberculosis drugs such as isoniazid, rifampin, perazinamide.
Major exclusion criteria: Patient’s displeasure to continue participation in the study; The incidence of drug-related complications.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Aspartate aminotransferase. Timepoint: 3 month. Method of measurement: International Unit per Milliliter.;Alanine aminotransferase. Timepoint: 3 month. Method of measurement: International Unit per Milliliter.

Secondary Outcome Measures

Name	Time	Method
Drug reaction. Timepoint: 3 month. Method of measurement: Questionnaire.